Spinally mediated analgesia and receptor binding affinity of epibatidine analogs

European Journal of Pharmacology

Volumn 470, Issue 1-2, 2003, Pages 27-31

  Nishiyama, Tomoki ^a,d   Gyermek, Laszlo ^b   Trudell, Mark L ^c   Hanaoka, Kazuo ^a  

^a UNIVERSITY OF TOKYO   (Japan)

^b HARBOR UCLA MEDICAL CENTER   (United States)

^c UNIVERSITY OF NEW ORLEANS   (United States)

^d NONE   (Japan)

Author keywords

Analgesia; Epibatidine; Nicotinic acetylcholine receptor; Radioligand; Spinal cord

Indexed keywords

2ALPHA (2 CHLOROPYRIDINYL) AZABICYCLO[3.2.1]OCTANE; 2BETA (2 CHLOROPYRIDINYL) AZABICYCLO[3.2.1]OCTANE; EPIBATIDINE; NICOTINIC RECEPTOR; OCTANE; UNCLASSIFIED DRUG;

AGITATION; ALLODYNIA; ANIMAL EXPERIMENT; ANIMAL TISSUE; ARTICLE; BINDING AFFINITY; BRAIN CORTEX; CONTROLLED STUDY; DOSE RESPONSE; DRUG EFFECT; DRUG POTENCY; MALE; MOTOR DYSFUNCTION; NONHUMAN; PRIORITY JOURNAL; RADIOASSAY; RAT; RECEPTOR BINDING; SPINAL ANESTHESIA; TAIL FLICK TEST;

EID: 0038699310     PISSN: 00142999     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0014-2999(03)01784-9     Document Type: Article

References (21)

1. Aceto M.D., Bagley R.S., Dewey W.L., Fu T.C., Martin B.R. The spinal cord as a major site for the antinociceptive action of nicotine in the rat. Neuropharmacology. 25:1986;1031-1036.
2. Bannon A.W., Gunther K.L., Zdecker M.W. Is epibatidine really analgesic? Dissociation of the activity, temperature, and analgesic effects of (±)-epibatidine. Pharmacol. Biochem. Behav. 51:1995;693-698.
3. Bencherif, M., Caldwell, W.S., Dull, G.M., Lippiello, P.M., 1996. Pharmaceutical compositions for the treatments of central nervous system disorders. Unites States Patent 5, 583, 140.
4. Bonhaus D.W., Bley K.R., Broka C.A., Fontana D.J., Leung E., Lewis R., Shieh A., Wong E.H.F. Characterization of the electrophysiological, biochemical and behavioral actions of epibatidine. J. Pharmacol. Exp. Ther. 272:1995;1199-1203.
5. Boyce B., Webb J.K., Shepheard S.L., Russell M.G.N., Hill R.G., Rupniak N.M.J. Analgesic and toxic effects of ABT-594 resemble epibatidine and nicotine in rats. Pain. 85:2000;443-450.
6. Fisher M., Huangfu D., Shen T.Y., Guyenet P.G. Epibatidine, an alkaloid from the poison frog epipedobates tricolor, is a powerful ganglionic depolarizing agent. J. Pharmacol. Exp. Ther. 270:1994;702-707.
7. Kanne D.B., Abood L.G. Synthesis and biological characterization of pyridohomotropanes. Structure-activity relationships of conformationally restricted nicotinoids. J. Med. Chem. 31:1988;505-509.
8. Kesingland A.C., Gentry C.T., Panesar M.S., Bowes M.A., Vernier J.M., Cube R., Walker K., Urban L. Analgesic profile of the nicotinic acethylcholine receptor agonists, (+)-epibatidine and ABT-594 in models of persistent inflammatory and neuropathic pain. Pain. 86:2000;113-118.
9. Khan I.M., Yaksh T.L., Taylor P. Epibatidine binding sites and activity in the spinal cord. Brain Res. 753:1997;269-282.
10. Lawand N.B., Lu Y., Westlund K.N. Nicotinic cholinergic receptors: potential targets for inflammatory pain relief. Pain. 80:1999;291-299.
11. Molinero M.T., Del Rio J. Substance P, nicotinic acetylcholine receptors and antinociception in the rat. Neuropharmacology. 26:1987;1715-1720.
12. Nishiyama T., Gyermek L., Lee C., Kawasaki-Yatsugi S., Yamaguchi T., Hanaoka K. The analgesic interaction between intrathecal clonidine and glutamate receptor antagonists on thermal and formalin-induced pain in rats. Anesth. Analg. 92:2001;725-732.
13. Qian C., Li T., Shen T.Y., Libertine-Garahan L., Eckman J., Biftu T., Ip S. Epibatidine is a nicotinic analgesic. Eur. J. Pharmacol. 250:1993;R13-R14.
14. Rogers D.T., Iwamoto E.T. Multiple spinal mediators in parenteral nicotine-induced antinociception. J. Pharmacol. Exp. Ther. 267:1993;341-349.
15. Sullivan J.P., Bannon A.W. Epibatidine: pharmacological properties of a novel nicotinic acetylcholine receptor agonist and analgesic agent. CNS Drugs. 2:1996;21-39.
16. Sullivan J.P., Briggs C.A., Donnelly-Roberts D., Brioni J.D., Radek R.J., McKenna D.G., Campbell J.E., Arneric S.P., Decker M.W., Bannon A.W. (±)-epibatidine can differentially evoke responses mediated by putative subtypes of nicotinic acetylcholine receptors (nAChRs). Med. Chem. Res. 4:1994;502-506.
17. Sullivan J.P., Decker M.W., Brioni J.D., Donnelly-Roberts D., Anderson D.J., Bannon A.W., Kang C.H., Adams P., Piattoni-Kaplan M., Buckley M.J., Gopalakrishman M., Williams M., Americ S.P. (±)-epibatidine elicits a diversity of in vitro and in vivo effects mediated by nicotinic acetylcholine receptors. J. Pharmacol. Exp. Ther. 271:1994;624-631.
18. Tallarida R.J., Murray R.B. Manual of Pharmacologic Calculation with Computer Programs. 1981;Springer-Verlag, New York.
19. Xu R., Bai D., Chu G., Tao J., Zhu X. Synthesis and analgesic activity of epibatidine analogues. Bioorg. Med. Chem. Lett. 6:1996;279-282.
20. Yaksh T.L., Rud T.A. Chronic catheterization of the spinal subarachnoid space. Physiol. Behav. 17:1976;1031-1036.
21. Zhang C., Gyermek L., Trudell M.L. Synthesis of optically pure epibatidine analogs: (1R, 2R, 5S)-2β-(2-chloropyridinyl) azabicyclo [3.2.1] octane and (1R, 2R, 5S)-2α-(2-chloropyridinyl) azabicyclo [3.2.1] octane from (-)-cocaine. Tetrahedron Lett. 38:1997;5619-5622.